Paper Review Records
全部论文审稿周期
4 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
114
天
Antisense Oligonucleotide STK-002 Increases OPA1 in Retina and Improves Mitochondrial Function in Autosomal Dominant Optic Atrophy Cells
作者
Aditya Venkatesh; Taylor McKenty; Syed Ali; Donna Sonntag; Shobha Ravipaty; Yanyan Cui; Deirdre Slate; Qian Lin; Anne Christiansen; Sarah Jacobson; Jacob Kach; Kian Huat Lim; Vaishnavi Srinivasan; Boris Zinshteyn; Isabel Aznarez; Laryssa A. Huryn; Zhiyu Li; Robert B. Hufnagel; Gene Liau; Karen Anderson; Jeff Hoger展开收起
作者单位
1. Stoke Therapeutics, Bedford, Massachusetts, USA.; 2. Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.展开收起
141
天
Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
作者
Judith van Deutekom; Chantal Beekman; Suzanne Bijl; Sieto Bosgra; Rani van den Eijnde; Dennis Franken; Bas Groenendaal; Bouchra Harquouli; Anneke Janson; Paul Koevoets; Melissa Mulder; Daan Muilwijk; Galyna Peterburgska; Bianca Querido; Janwillem Testerink; Ruurd Verheul; Peter de Visser; Rudie Weij; Annemieke Aartsma-Rus; Jukka Puoliväli; Timo Bragge; Charles O'Neill; Nicole A. Datson展开收起
作者单位
1. VICO Therapeutics B.V., formerly BioMarin Nederland B.V., Leiden, The Netherlands.; 2. Department of Human Genetics, Leiden University Medical Centre, Leiden, The Netherlands.; 3. Charles River Discovery Services, Kuopio, Finland.; 4. BioMarin Pharmaceutical, Inc., San Rafael, California, USA.展开收起
117
天
Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in hERG Assays
作者
Yusheng Qu; Robert Kirby; Richard Davies; Ayesha Jinat; Stefano Stabilini; Bin Wu; Longchuan Yu; BaoXi Gao; Hugo M. Vargas展开收起
作者单位
1. Amgen Research, Translational Safety and Bioanalytical Sciences, Amgen, Inc., Thousand Oaks, California, USA.; 2. Metrion Biosciences Ltd, Granta Center, Cambridge, United Kingdom.; 3. Hybrid Modality Engineering, Amgen, Inc., Thousand Oaks, California, USA.; 4. Cardiometabolic Disorders, Amgen, Inc., Thousand Oaks, California, USA.展开收起
35
天
Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides
作者
Annemieke Aartsma-Rus; Alejandro Garanto; Willeke van Roon-Mom; Erin M. McConnell; Victoria Suslovitch; Winston X. Yan; Jonathan K. Watts; Timothy W. Yu展开收起
作者单位
1. Dutch Center for RNA Therapeutics, the Netherlands.; 2. Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.; 3. N = 1 Collaborative.; 4. Department of Pediatrics and Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.; 5. Department of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, USA.; 6. RNA Therapeutics Institute, UMass Chan Medical School, Worcester, Massachusetts, USA.; 7. Harvard Medical School, Division of Genetics and Genomics, Boston, Massachusetts, USA.展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天